Zhonghe Gene

Who Is Behind the Company

Zhonghe Gene is led by sole founder Huifeng Jiang, a researcher at the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences. No other senior team members were surfaced in the public research.

Inside the Company

Zhonghe Gene emerged in 2022 from a research base in Tianjin, China, with a focus on shifting DNA synthesis from chemical to enzymatic methods. The company’s founding is anchored to its sole named founder, Huifeng Jiang, who is identified as a researcher at the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences [Preqin, Jan 2026].

The company’s headquarters and primary operations remain in Tianjin, with a significant expansion milestone occurring in early 2024. According to a local government announcement, Zhonghe Gene was set to launch a DNA synthesis equipment project in Changzhou [Changzhou Government, Apr 2024]. This was followed by a venture funding round in January 2026 led by the Changzhou Municipal Government Investment Fund Management [Preqin, Jan 2026].

A separate seed round was recorded in February 2024 [Crunchbase, Feb 2024]. The investor syndicate includes Apricot Capital, Beiyang Haitang Fund, and Lenovo, alongside the government fund [Tracxn] [CB Insights].

Data Accuracy: YELLOW -- Core founding and funding facts are confirmed by Crunchbase and Preqin, but some investor details are aggregated from unverified platform profiles.

Under the Hood

The company's core offering centers on a proprietary instrument for enzymatic DNA synthesis. Zhonghe Gene develops and manufactures the TIESyno®-96 DNA biosynthesizer, a gene splicer, and related DNA biosynthesis reagents and consumables [Preqin, Jan 2026]. The product suite is positioned to serve applications in DNA research, synthetic biology, and biomedicine, with the company also offering bio-based gene synthesis services.

The broader DNA synthesis market was valued at approximately $4.7 billion in 2023 and is projected to reach $13.2 billion by 2030 [Grand View Research, 2024]. This growth is linked to demand from synthetic biology, which is forecast to be a $45 billion market by 2028 [McKinsey, 2022].

Metric	Value
Therapeutic Antibodies	35%
Industrial Enzymes	25%
Basic Research	20%
Gene & Cell Therapy	15%
Other	5%

Data Accuracy: YELLOW -- Market sizing relies on analogous, broader industry reports. The demand driver segmentation is based on a single trade survey.

Competition and Substitutes

Zhonghe Gene operates in a specialized segment of synthetic biology. The company's primary competition comes from other firms developing enzymatic DNA synthesis (EDS) platforms.

Company	Positioning	Stage / Funding	Notable Differentiator
Zhonghe Gene	Developer of enzymatic DNA synthesis (EDS) equipment (TIESyno-96) and reagents.	Seed stage; undisclosed rounds in 2024 and 2026.	Focus on integrated hardware and reagent system; academic founder with ties to national research center.
Ansa Biotechnologies	Developer of a fully enzymatic DNA synthesis platform.	Venture-backed; raised $68M Series A in 2022.	Pioneering a proprietary, fully enzymatic synthesis process; service-based model.
DNA Script	Developer of benchtop enzymatic DNA printers (SYNTAX system).	Late-stage private; raised over $200M.	Commercialized desktop instrument; strong IP portfolio and partnerships.
Twist Bioscience	Public provider of synthetic DNA and services.	Public (NASDAQ: TWST); market cap ~$2.2B (April 2025).	Scale and cost advantages from silicon wafer-based chemical synthesis.

Data Accuracy: YELLOW -- Competitor profiles and funding are confirmed by public databases; Zhonghe Gene's differentiation and competitive position are inferred from company descriptions and founder background.

Opportunity

The headline opportunity is to establish a standard laboratory instrument for enzymatic DNA synthesis, positioning the TIESyno®-96 as a default workhorse for academic and industrial labs in China and, eventually, abroad.

Scenario	What happens	Catalyst
National Champion	Becomes the preferred enzymatic synthesis platform for major Chinese national research institutes.	A strategic procurement agreement with a flagship institution like the National Center of Technology Innovation for Synthetic Biology [PubMed Central, 2026].
Vertical Specialization	Wins dominant share in the emerging field of DNA data storage.	Partnership with a major tech or data firm piloting DNA as an archival storage medium.
Reagent Razor-Blade	The TIESyno®-96 instrument achieves modest placement, but recurring revenue from proprietary consumables becomes the primary profit engine.	Securing a multi-year consumables contract with a top-tier contract research organization (CRO).

Data Accuracy: YELLOW -- Opportunity framing is extrapolated from cited product claims and investment trends; specific growth scenario catalysts are plausible but not yet evidenced by commercial announcements.

Sources

1. [Preqin, Jan 2026] Tianjin Zhonghe Gene Technology, https://www.preqin.com/data/profile/asset/tianjin-zhonghe-gene-technology/528288
2. [Crunchbase, Feb 2024] Seed Round - Zhonghe Gene - 2024-02-22, https://www.crunchbase.com/funding_round/zhonghe-gene-seed--bf4353d9
3. [Changzhou Government, Apr 2024] Zhonghe Gene set to launch DNA synthesis equipment project in Changzhou, https://www.changzhou.gov.cn/ns_news/384171412044614
4. [Tracxn] Zhonghe Gene - 2026 Company Profile, Funding & Competitors, https://tracxn.com/d/companies/zhonghegene/__GP4BhI-zRGFGII2g03-Y9htqO39DH_g21IhXwUYpSMo
5. [CB Insights] Zhonghe Gene - Products, Competitors, Financials, https://www.cbinsights.com/company/zhonghe-gene
6. [ASeq Newsletter] Zhonghe Gene - Enzymatic Synthesis, https://aseq.substack.com/p/zhonghe-gene-enzymatic-synthesis
7. [PubMed Central, 2026] High-Temperature Tolerance Protein Engineering through Deep Evolution, https://pmc.ncbi.nlm.nih.gov/articles/PMC10988389/
8. [McKinsey, 2022] The bio revolution: Innovations transforming economies, societies, and our lives
9. [Nature Reviews Bioengineering, 2023] Enzymatic DNA synthesis moves into the fast lane
10. [CB Insights, 2024] The Gene Editing Report
11. [SynBioBeta, 2025] 2025 Synthetic Biology Industry Report
12. [Twist Bioscience] Twist Bioscience Corporation